Capricor Therapeutics Inc (CAPR)
6.20
+0.56
(+9.93%)
USD |
NASDAQ |
May 17, 16:00
6.22
+0.02
(+0.32%)
After-Hours: 20:00
Capricor Therapeutics Research and Development Expense (Quarterly): 11.10M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 11.10M |
| December 31, 2023 | 9.940M |
| September 30, 2023 | 10.03M |
| June 30, 2023 | 8.817M |
| March 31, 2023 | 7.662M |
| December 31, 2022 | 6.232M |
| September 30, 2022 | 5.504M |
| June 30, 2022 | 4.965M |
| March 31, 2022 | 5.116M |
| December 31, 2021 | 4.264M |
| September 30, 2021 | 2.514M |
| June 30, 2021 | 3.497M |
| March 31, 2021 | 3.296M |
| December 31, 2020 | 2.745M |
| September 30, 2020 | 2.629M |
| June 30, 2020 | 1.928M |
| March 31, 2020 | 1.155M |
| December 31, 2019 | 0.8287M |
| September 30, 2019 | 0.8578M |
| June 30, 2019 | 1.644M |
| March 31, 2019 | 1.811M |
| December 31, 2018 | 2.849M |
| September 30, 2018 | 3.132M |
| June 30, 2018 | 3.389M |
| March 31, 2018 | 2.696M |
| Date | Value |
|---|---|
| December 31, 2017 | 2.518M |
| September 30, 2017 | 1.862M |
| June 30, 2017 | 3.128M |
| March 31, 2017 | 3.257M |
| December 31, 2016 | 2.666M |
| September 30, 2016 | 4.727M |
| June 30, 2016 | 4.308M |
| March 31, 2016 | 4.341M |
| December 31, 2015 | 3.331M |
| September 30, 2015 | 3.193M |
| June 30, 2015 | 3.427M |
| March 31, 2015 | 3.807M |
| December 31, 2014 | 2.584M |
| September 30, 2014 | 1.967M |
| June 30, 2014 | 1.856M |
| March 31, 2014 | 1.375M |
| December 31, 2013 | 1.684M |
| September 30, 2013 | 1.010M |
| June 30, 2013 | 1.312M |
| March 31, 2013 | 1.191M |
| December 31, 2012 | 1.657M |
| September 30, 2012 | 0.1791M |
| June 30, 2012 | |
| March 31, 2012 | 0.4654M |
| December 31, 2011 | 1.342M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.8287M
Minimum
Dec 2019
11.10M
Maximum
Mar 2024
4.736M
Average
3.880M
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 200.40M |
| PTC Therapeutics Inc | 116.13M |
| Solid Biosciences Inc | 18.87M |
| Inovio Pharmaceuticals Inc | 20.91M |
| Stereotaxis Inc | 2.243M |